Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Intestinal Inhibition of the Na + /H + Exchanger 3 Prevents Cardiorenal Damage in Rats and Inhibits Na + Uptake in Humans
Andrew Spencer, Eric D. Labonté, David P. Rosenbaum, et al.
Science Translational Medicine (2014) Vol. 6, Iss. 227
Closed Access | Times Cited: 142

Showing 1-25 of 142 citing articles:

Physiology of Intestinal Absorption and Secretion
Pawel R. Kiela, Fayez K. Ghishan
Best Practice & Research Clinical Gastroenterology (2016) Vol. 30, Iss. 2, pp. 145-159
Open Access | Times Cited: 572
Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure
Milton Packer, Stefan D. Anker, Javed Butler, et al.
JAMA Cardiology (2017) Vol. 2, Iss. 9, pp. 1025-1025
Closed Access | Times Cited: 320
New Approaches in the Treatment of Hypertension
Suzanne Oparil, Roland E. Schmieder
Circulation Research (2015) Vol. 116, Iss. 6, pp. 1074-1095
Closed Access | Times Cited: 256
The SLC9A-C Mammalian Na+/H+Exchanger Family: Molecules, Mechanisms, and Physiology
Stine F. Pedersen, Laurent Counillon
Physiological Reviews (2019) Vol. 99, Iss. 4, pp. 2015-2113
Closed Access | Times Cited: 151
AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Constipation
Lin Chang, Shahnaz Sultan, Anthony Lembo, et al.
Gastroenterology (2022) Vol. 163, Iss. 1, pp. 118-136
Open Access | Times Cited: 102
Gut microbiota in hypertension
Pedro A. José, Dominic S. Raj
Current Opinion in Nephrology & Hypertension (2015) Vol. 24, Iss. 5, pp. 403-409
Open Access | Times Cited: 176
Development and Characterization of a Human and Mouse Intestinal Epithelial Cell Monolayer Platform
Kenji Kozuka, Ying He, Samantha Koo-McCoy, et al.
Stem Cell Reports (2017) Vol. 9, Iss. 6, pp. 1976-1990
Open Access | Times Cited: 153
Inhibition of sodium/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor reduces paracellular phosphate permeability
Andrew J. King, Matthew Siegel, Ying He, et al.
Science Translational Medicine (2018) Vol. 10, Iss. 456
Open Access | Times Cited: 129
New treatments and therapeutic targets for IBS and other functional bowel disorders
Magnus Simrén, Jan Tack
Nature Reviews Gastroenterology & Hepatology (2018) Vol. 15, Iss. 10, pp. 589-605
Closed Access | Times Cited: 126
Efficacy and Safety of Tenapanor in Patients with Hyperphosphatemia Receiving Maintenance Hemodialysis: A Randomized Phase 3 Trial
Geoffrey A. Block, David P. Rosenbaum, Andrew T. Yan, et al.
Journal of the American Society of Nephrology (2019) Vol. 30, Iss. 4, pp. 641-652
Open Access | Times Cited: 105
Regulation and Effects of FGF23 in Chronic Kidney Disease
John Musgrove, Myles Wolf
Annual Review of Physiology (2019) Vol. 82, Iss. 1, pp. 365-390
Closed Access | Times Cited: 105
Hypertension as a Metabolic Disorder and the Novel Role of the Gut
Masami Tanaka, Hiroshi Itoh
Current Hypertension Reports (2019) Vol. 21, Iss. 8
Open Access | Times Cited: 104
Gastrointestinal Inhibition of Sodium-Hydrogen Exchanger 3 Reduces Phosphorus Absorption and Protects against Vascular Calcification in CKD
Eric D. Labonté, Christopher W. Carreras, Michael R. Leadbetter, et al.
Journal of the American Society of Nephrology (2014) Vol. 26, Iss. 5, pp. 1138-1149
Open Access | Times Cited: 100
Effect of Tenapanor on Serum Phosphate in Patients Receiving Hemodialysis
Geoffrey A. Block, David P. Rosenbaum, Maria Leonsson‐Zachrisson, et al.
Journal of the American Society of Nephrology (2017) Vol. 28, Iss. 6, pp. 1933-1942
Open Access | Times Cited: 95
Tenapanor Treatment of Patients With Constipation-Predominant Irritable Bowel Syndrome: A Phase 2, Randomized, Placebo-Controlled Efficacy and Safety Trial
William D. Chey, Anthony Lembo, David P. Rosenbaum
The American Journal of Gastroenterology (2017) Vol. 112, Iss. 5, pp. 763-774
Open Access | Times Cited: 89
Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 12-Week, Placebo-Controlled Phase 3 Trial (T3MPO-1)
William D. Chey, Anthony Lembo, David P. Rosenbaum
The American Journal of Gastroenterology (2020) Vol. 115, Iss. 2, pp. 281-293
Open Access | Times Cited: 78
Gut microbiota dependant trimethylamine N-oxide and hypertension
Katongo Hope Mutengo, Sepiso K. Masenga, Aggrey Mweemba, et al.
Frontiers in Physiology (2023) Vol. 14
Open Access | Times Cited: 23
NHE3 inhibitor tenapanor maintains intestinal barrier function, decreases visceral hypersensitivity, and attenuates TRPV1 signaling in colonic sensory neurons
Andrew J. King, Lin Chang, Qian Li, et al.
AJP Gastrointestinal and Liver Physiology (2024) Vol. 326, Iss. 5, pp. G543-G554
Open Access | Times Cited: 10
Intestinal SGLT1 in metabolic health and disease
Anders Lehmann, Pamela J. Hornby
AJP Gastrointestinal and Liver Physiology (2016) Vol. 310, Iss. 11, pp. G887-G898
Open Access | Times Cited: 84
Gut microbiota, hypertension and chronic kidney disease: Recent advances
Antonio Sircana, Franco De Michieli, Renato Parente, et al.
Pharmacological Research (2018) Vol. 144, pp. 390-408
Closed Access | Times Cited: 71
Pathophysiology of Intestinal Na+/H+ Exchange
Michael A. Gurney, Daniel Laubitz, Fayez K. Ghishan, et al.
Cellular and Molecular Gastroenterology and Hepatology (2016) Vol. 3, Iss. 1, pp. 27-40
Open Access | Times Cited: 61
Update S3-Leitlinie Reizdarmsyndrom: Definition, Pathophysiologie, Diagnostik und Therapie. Gemeinsame Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) und der Deutschen Gesellschaft für Neurogastroenterologie und Motilität (DGNM) – Juni 2021 – AWMF-Registriernummer: 021/016
Peter Layer, Viola Andresen, H.‐D. Allescher, et al.
Zeitschrift für Gastroenterologie (2021) Vol. 59, Iss. 12, pp. 1323-1415
Open Access | Times Cited: 55
Heart Failure: a Punch from the Gut
Ajay Mahenthiran, Jennifer Wilcox, W.H. Wilson Tang
Current Heart Failure Reports (2024) Vol. 21, Iss. 2, pp. 73-80
Open Access | Times Cited: 8
Tenapanor as Therapy for Hyperphosphatemia in Maintenance Dialysis Patients: Results from the OPTIMIZE Study
Stuart M. Sprague, Daniel E. Weiner, David P. Tietjen, et al.
Kidney360 (2024) Vol. 5, Iss. 5, pp. 732-742
Open Access | Times Cited: 7
Gut hormones and gut microbiota: implications for kidney function and hypertension
Barış Afşar, Nosratola D. Vaziri, Gamze Aslan, et al.
Journal of the American Society of Hypertension (2016) Vol. 10, Iss. 12, pp. 954-961
Open Access | Times Cited: 57
Page 1 - Next Page

Scroll to top